Fruquintinib vs bevacizumab for second-line metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares two drug combinations for patients whose colorectal cancer has spread and worsened after first treatment. You would receive either FOLFOX or FOLFIRI plus fruquintinib, or the same chemo plus bevacizumab, to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old (if over 75, you must pass a short health questionnaire).
- You have metastatic colorectal cancer that has grown after first-line treatment that included bevacizumab or an EGFR inhibitor with FOLFOX or FOLFIRI.
- Your cancer cannot be surgically removed and you have at least one measurable tumor.
- You are in good enough health to be up and about (WHO performance status 0 or 1).
- Your blood counts, liver and kidney function are within certain limits, and you have no uncontrolled high blood pressure or recent heart problems.
- You have not received more than one prior systemic therapy for metastatic disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well fruquintinib works for people with advanced colorectal cancer that has spread. It aims to find factors that predict better outcomes, using blood and tumor samples.
This trial tests if a newer targeted drug (fruquintinib) works as well as a standard drug (bevacizumab) when combined with two chemotherapy drugs for people with advanced colorectal cancer that got worse after first treatment. It aims to find a better option for second-line treatment.
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
This trial compares two treatments for people with a specific type of advanced colorectal cancer that has a RAS mutation. It tests if fruquintinib works as well as the standard combination of bevacizumab and chemotherapy in people who have already had one round of chemotherapy.
This trial compares two combination treatments for people with advanced colorectal cancer that has stopped responding to standard therapies. You would receive either trifluridine/tipiracil plus fruquintinib or trifluridine/tipiracil plus bevacizumab, to see which combination works better.
This trial tests a new combination—fruquintinib (a targeted pill) plus TAS-102 (another chemo pill)—against a standard regimen of bevacizumab (Avastin) plus TAS-102 for people whose advanced colorectal cancer has continued to grow after multiple prior treatments.
Hear when a new Metastatic Colorectal Carcinoma (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.